Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
30
MDGL Quote, Financials, Valuation and Earnings
Last price:
$444.70
Seasonality move
:
1.33%
Day range:
$426.04 - $438.00
52-week range:
$265.00 - $615.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
10.40x
P/B ratio:
16.76x
Volume:
220.8K
Avg. volume:
375K
1-year change:
28.67%
Market cap:
$10.1B
Revenue:
$958.4M
EPS (TTM):
-$12.86
Analysts' Opinion
-
Consensus RatingMadrigal Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $667.57, Madrigal Pharmaceuticals, Inc. has an estimated upside of 50.07% from its current price of $431.53.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $529.00 representing 100% downside risk from its current price of $431.53.
Fair Value
-
According to the consensus of 13 analysts, Madrigal Pharmaceuticals, Inc. has 50.07% upside to fair value with a price target of $667.57 per share.
MDGL vs. S&P 500
-
Over the past 5 trading days, Madrigal Pharmaceuticals, Inc. has overperformed the S&P 500 by 2.23% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Madrigal Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Madrigal Pharmaceuticals, Inc. has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Madrigal Pharmaceuticals, Inc. reported revenues of $321.1M.
Earnings Growth
-
Madrigal Pharmaceuticals, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Madrigal Pharmaceuticals, Inc. reported earnings per share of -$2.57.
Enterprise value:
9.5B
EV / Invested capital:
9.96x
Price / LTM sales:
10.40x
EV / EBIT:
--
EV / Revenue:
9.87x
PEG ratio (5yr expected):
-1.39x
EV / Free cash flow:
-49.02x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$900.7M
Return On Assets:
-25.39%
Net Income Margin (TTM):
-30.08%
Return On Equity:
-42.53%
Return On Invested Capital:
-32.42%
Operating Margin:
-18.57%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | -- | $180.1M | $958.4M | $103.3M | $321.1M | |
| Gross Profit | -$527K | $172.8M | $900.7M | $99.5M | $296.2M | |
| Operating Income | -$380.5M | -$497.9M | -$300.1M | -$67M | -$59.6M | |
| EBITDA | -$380M | -$496.8M | -$298.6M | -$66.6M | -$59.2M | |
| Diluted EPS | -$19.94 | -$22.11 | -$12.86 | -$2.71 | -$2.57 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $271.7M | $361.4M | $637.3M | $1B | $1.2B | |
| Total Assets | $273.3M | $362.6M | $640.5M | $1B | $1.3B | |
| Current Liabilities | $76.8M | $115.9M | $118.5M | $169.3M | $310.3M | |
| Total Liabilities | $77.2M | $165.2M | $235.2M | $287.9M | $656.9M | |
| Total Equity | $196.1M | $197.4M | $405.3M | $754.4M | $602.7M | |
| Total Debt | $387K | $49.3M | $116.7M | $118.6M | $346.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$324.2M | -$455.6M | -$189.6M | -$104.5M | -$133.5M | |
| Cash From Investing | -$502.5M | -$274.4M | $32.3M | -$48M | $27.6M | |
| Cash From Financing | $595.1M | $735.1M | $256M | $19.8M | $9M | |
| Free Cash Flow | -$325.7M | -$462M | -$193M | -$104.7M | -$133.1M | |
MDGL
Sector
Market Cap
$10.1B
$25.1M
Price % of 52-Week High
72.33%
48.72%
Dividend Yield
0%
0%
Shareholder Yield
-0.63%
-1.6%
1-Year Price Total Return
37.71%
-18.38%
Beta (5-Year)
-0.970
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$433.24
200-day SMA
Buy
Level
$431.33
Bollinger Bands (100)
Sell
Level
445.43 - 564.57
Chaikin Money Flow
Buy
Level
66.5K
20-day SMA
Sell
Level
$446.34
Relative Strength Index (RSI14)
Sell
Level
37.91
ADX Line
Sell
Level
16.56
Williams %R
Neutral
Level
-20.698
50-day SMA
Sell
Level
$487.61
MACD (12, 26)
Buy
Level
96.18
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Sell
Level
-722.9K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (10.6225)
Sell
CA Score
(Annual)
Level (-0.9024)
Sell
Beneish M-Score
(Annual)
Level (0.4709)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.3593)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.
Stock Forecast FAQ
In the current month, MDGL has received 11 Buy ratings 2 Hold ratings, and 0 Sell ratings. The MDGL average analyst price target in the past 3 months is $667.57.
-
Where Will Madrigal Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Madrigal Pharmaceuticals, Inc. share price will rise to $667.57 per share over the next 12 months.
-
What Do Analysts Say About Madrigal Pharmaceuticals, Inc.?
Analysts are divided on their view about Madrigal Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Madrigal Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $529.00.
-
What Is Madrigal Pharmaceuticals, Inc.'s Price Target?
The price target for Madrigal Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $667.57 according to 13 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is MDGL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Madrigal Pharmaceuticals, Inc. is a Buy. 11 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MDGL?
You can purchase shares of Madrigal Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Madrigal Pharmaceuticals, Inc. shares.
-
What Is The Madrigal Pharmaceuticals, Inc. Share Price Today?
Madrigal Pharmaceuticals, Inc. was last trading at $444.70 per share. This represents the most recent stock quote for Madrigal Pharmaceuticals, Inc.. Yesterday, Madrigal Pharmaceuticals, Inc. closed at $431.53 per share.
-
How To Buy Madrigal Pharmaceuticals, Inc. Stock Online?
In order to purchase Madrigal Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get MDGL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MDGL
Sector
P/E ratio
--
21.37x
PEG ratio
-1.39x
-0.01x
P/B ratio
16.76x
1.73x
Price / LTM sales
10.40x
1.46x
Growth Metrics
MDGL
Sector
Revenue growth
210.77%
3.27%
Earnings growth
5.3%
12.13%
Revenue (5-year growth)
--
6.25%
Earnings forecast
-$0.88
-$0.20
Profitability
MDGL
Sector
Profitability FY 2025
$900.7M
$2.3M
Return on invested capital
-32.42%
-33.43%
Return on assets
-25.39%
-29.94%
Return on equity
-42.53%
-40.07%
Earnings Date
Last Earnings Date
Feb
19
Next Earnings Date
Apr
30
Estimated Next Earnings Date
May
21
Balance Sheet
MDGL
Sector
Total cash
$988.6M
$24.9M
Short term investments
$826.2M
$23M
Total assets
$1.3B
$70.1M
Long term debt
$346.6M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
92
APEI alert for Mar 13
American Public Education, Inc. [APEI] is up 26.24% over the past day.
Buy
52
PZZA alert for Mar 13
Papa John's International, Inc. [PZZA] is down 5.25% over the past day.
Buy
53
NBIS alert for Mar 13
Nebius Group NV [NBIS] is up 0.87% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
